Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial

Vaccine

Volumn 29, Issue 25, 2011, Pages 4274-4284

  Vesikari, Timo ^a   Karvonen, Aino ^a   Bianco, Veronique ^b   Van der Wielen, Marie ^b   Miller, Jacqueline ^c  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Bactericidal activity; Conjugate vaccine; Measles mumps rubella varicella vaccine; Tetravalent meningococcal vaccine

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE;

ARTICLE; CHICKENPOX; CHILD; DEATH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MEASLES; MENINGOCOCCOSIS; MUMPS; OPEN STUDY; PAROTID GLAND DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RUBELLA; SALIVARY GLAND DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; FEVER; HUMANS; INFANT; MEASLES-MUMPS-RUBELLA VACCINE; MENINGOCOCCAL VACCINES; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 79956213992     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.043     Document Type: Article

References (40)

1. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007, 31:27-36.
2. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27:B51-B63.
3. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004, 23:S274-S279.
4. Vermont C.L., van den Dobbelsteen G.P.J.M. Meningococcal serogroup B infections: a search for a broadly protective vaccine. Expert Rev Vaccines 2003, 2:673-681.
5. Health Protection Agency, London. Invasive Neisseria meningitidis in Europe 2006 [Internet]. EU-IBIS. European Union Invasive Bacteria Infections Surveillance Network; 2006. Available from: http://www.euibis.org/.
6. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5:21-30.
7. Aguilera J., Perrocheau A., Meffre C., Hahné S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 2002, 8:761-767.
8. De Wals P., De Serres G., Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001, 285:177-181.
9. Larrauri A., Cano R., García M., Mateo S.D. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
10. Booy R., Jelfs J., El Bashir H., Nissen M.D. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 2007, 186:108-109.
11. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20:S58-S67.
12. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006, 25:79-80.
13. Pace D., Pollard A.J. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child 2007, 92:909-915.
14. MENVEO® Meningococcal Group A, C, W135 and Y conjugate vaccine. Summary of Product Characterstics. Novartis Vaccines.2010 [Internet]. Available from: http://www.medicines.org.uk/emc/medicine/22866/SPC/Menveo%2520Group%2520A,%2520C,%2520W135%2520and%2520Y%2520conjugate%2520vaccine.
15. Knuf M., Kieninger-Baum D., Habermehl P., Muttonen P., Maurer H., Vink P., et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010, 28:744-753.
16. Ostergaard L., Lebacq E., Poolman J., Maechler G., Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009, 27:161-168.
17. Vesikari T., Karvonen A., Lindblad N., Poolman J., Boutriau D. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 1-2 year-olds. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases 2009.
18. Vesikari T., Sadzot-Delvaux C., Rentier B., Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J 2007, 26:632-638.
19. Klein N.P., Fireman B., Yih W.K., Lewis E., Kulldorff M., Ray P., et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010, 126:e1-e8.
20. Freed G.L., Cowan A.E., Clark S.J., Santoli J., Bradley J. Use of a new combined vaccine in pediatric practices. Pediatrics 2006, 118:e251-e257.
21. Meyerhoff A.S., Jacobs R.J. Do too many shots due lead to missed vaccination opportunities? Does it matter?. Prev Med 2005, 41:540-544.
22. Knuf M., Habermehl P., Zepp F., Mannhardt W., Kuttnig M., Muttonen P., et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006, 25:12-18.
23. Nolan T., McIntyre P., Roberton D., Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002, 21:281-289.
24. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
25. Centers for Disease Control and Prevention Inadvertent misadministration of meningococcal conjugate vaccine - United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006, 55:1016-1017.
26. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997, 4:156-167.
27. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
28. Granoff D.M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009, 27:B117-B125.
29. Jodar L., Cartwright K., Feavers I.M. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000, 28:193-197.
30. World Health Organization. Recommendations to assure the quality, safety, and efficacy of group A meningococcal conjugate vaccines. WHO/BS/0.62041.
31. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786.
32. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69:1568-1573.
33. Schuster V., Otto W., Maurer L., Tcherepnine P., Pfletschinger U., Kindler K., et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 2008, 27:724-730.
34. Strebel P.M., Papania M., Halsey N. Measles vaccine. Vaccines 2004, 389-440. Saunders Elsevier, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
35. Vesikari T., Baer M., Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5-6 years. Pediatr Infect Dis J 2007, 26:153-158.
36. Czajka H., Schuster V., Zepp F., Esposito S., Douha M., Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009, 27:6504-6511.
37. Borrow R., Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev Vaccines 2009, 8:265-279.
38. Díez-Domingo J., Cantarino M.V.P., Torrentí J.M.B., Sansano M.I.U., Rosich A.J., Merino A.H., et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14-18 months. Pediatr Infect Dis J 2010, 29:148-152.
39. Borrow R., Andrews N., Findlow H., Waight P., Southern J., Crowley-Luke A., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010, 17:154-159.
40. Carmona A., Miranda M., Barrio F., De Vicente A., Mares J., Muñoz E., et al. Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine. Pediatr Infect Dis J 2010, 29:269-271.